New hope for advanced cancer patients: experimental drug IPN01203 enters human trials
NCT ID NCT07213830
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 27 times
Summary
This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to standard immunotherapy. The goal is to find a safe and effective dose that can slow or stop tumor growth. Participants receive the drug and are monitored closely with blood tests, scans, and check-ups for as long as they benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
-
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) - PI Ronan
NOT_YET_RECRUITINGVillejuif, France
-
Hospital Universitario Vall d'Hebron PI Garralda Cabanas
NOT_YET_RECRUITINGBarcelona, Spain
-
MD Anderson PI Champiat
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
NEXT PI Spira
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
-
NEXT Quiron-Barcelona - PI Saavedra Santa Gadea
RECRUITINGBarcelona, Spain
-
Princess Margaret Cancer Center PI Spreafico
RECRUITINGToronto, Canada
-
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC) - Calvo Aller
RECRUITINGMadrid, Spain
-
START MidWest PI Sharma
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute PI McKean Nasville, TN, USA
RECRUITINGNashville, Tennessee, 37205, United States
-
Start San Antonio PI Rasco
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.